Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.48 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34473065 | 0.96 | ALDH1A1 (0.56) | ALDH1A1LMNAMAPTCYP1A2CYP2D6 | |
| SCHEMBL14441549 | 0.89 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTCYP1A2CYP2D6 | |
| SCHEMBL18497575 | 0.89 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTCYP1A2CYP2D6 | |
| SCHEMBL31441502 | 0.87 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPTCYP1A2CYP2D6 | |
| SCHEMBL31441498 | 0.87 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPTCYP1A2CYP2D6 | |
| SCHEMBL1559097 | 0.86 | MAPT (0.53) | ALDH1A1LMNAMAPTCYP1A2CYP2D6 | |
| SCHEMBL596980 | 0.86 | GPR119 (0.64) | ALDH1A1LMNAMAPTCYP1A2CYP2D6 | |
| SCHEMBL313831 | 0.84 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTCYP1A2CYP2D6 | |
| SCHEMBL2830265 | 0.83 | CYP1A2 (0.52) | ALDH1A1MAPTCYP1A2CYP2D6MGLL | |
| SCHEMBL392783 | 0.83 | ALDH1A1 (0.72) | ALDH1A1LMNAMAPTCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463450-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | Bisichem Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-11-07 | — | — | US | disclosed |
| CN-118510770-A | Fused heteroaryl hydroxamic acids as STING agonists | 比西切姆有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023136589-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | BISICHEM CO., LTD. (KR) | 2023-07-20 | — | — | WO | disclosed |
| US-20230219931-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | BISICHEM CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219931-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | BISICHEM CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| EP-4146660-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| CN-115605488-A | Bifunctional degradants of hematopoietic progenitor kinases and therapeutic uses thereof | 新锐思生物制药股份有限公司（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| EP-1562901-B1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7476681-B2 | anticarcinogenic agent; prostate cancer, benign prostatic hyperplasia, prostatic intraepithelial neoplasia, hirsutism, acne, androgenic alopecia, or polycystic ovary syndrome, prostate, lung, pancreatic, colon, renal cancer, myeloid leukemia | SCHERING CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476681-B2 | anticarcinogenic agent; prostate cancer, benign prostatic hyperplasia, prostatic intraepithelial neoplasia, hirsutism, acne, androgenic alopecia, or polycystic ovary syndrome, prostate, lung, pancreatic, colon, renal cancer, myeloid leukemia | SCHERING CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | HRH4, HRH2, HRH1 | ALDH1A1 1903/4885LMNA 4752/4885MAPT 3212/4885 |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | HRH4, HRH2, HRH1 | ALDH1A1 2399/4885LMNA 4814/4885MAPT 2968/4885 |
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | HYPK, PGK1, HIPK1 | ALDH1A1 2946/4885LMNA 2018/4885MAPT 2516/4885 |
| US-20230219931-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | STING1, IRF3, IFNAR1 | ALDH1A1 4617/4885LMNA 2977/4885MAPT 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.